Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in
different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab,
can block cancer growth in different ways. Some block the ability of cancer cells to grow and
spread. Others find cancer cells and help kill them or carry cancer-killing substances to
them. Giving lenalidomide together with rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving lenalidomide together with rituximab
works in treating patients with follicular or small lymphocytic non-Hodgkin lymphoma that has
relapsed or not responded to treatment.